157
Participants
Start Date
December 18, 2016
Primary Completion Date
April 26, 2018
Study Completion Date
July 31, 2018
Botulinum toxin type A
Dysport® administered in both upper and lower limbs (total dose of 1500 U per injection split between the 2 limbs).
GSC
The GSC is a motivational tool. The physiotherapist will teach each subject the stretching postures and exercises to perform on a daily basis throughout the study. These will be tailored to the individual subject's needs and will form the GSC therapy.
University of Pittsburgh Medical Center, Physical Medicine and Rehabilitation, Pittsburgh
Medical University of South Carolina, Charleston
Service de Médecine Physique et de Réadaptation, Bâtiment Tastet-Girard, Groupe Hospitalier Pellegrin, Bordeaux
Service de Médecine Physique et Réadaptation, CHU Saint Etienne - Hôpital Bellevue, Saint-Etienne
Service de Médecine Physique et Réadaptation, Hôpital Sébastopol - CHU de Reims, Reims
Kansas Institute of Research, Kansas City Bone & Joint Clinic, Division of Signature Medical Group of KC, Kansas City
UT Southwestern Medical Center, Dallas
UT Health Physical Medicine & Rehabilitation Department, TIRR Memorial Hermann, Houston
Service de Médecine Physique et Réadaptation, Hôpital Albert-Chenevier, Créteil
Medical Rehabilitation Center, Moscow
Saint-Petersburg Bekhterev Psychoneurological Research Institute, Saint Petersburg
Samara Regional Clinical Hospital n.a. V.D.Seredavin, Samara
Federal Siberian Scientific Clinical Center, Krasnoyarsk
Department of Neurology, Division of Movement Disorders, Vanderbilt University, Nashville
Fakultní nemocnice Královské Vinohrady, Neurologická klinika, Brno
Neurology and Physiotherapy Outpatient Clinic, Brno
Fakultní nemocnice Brno Neurologická klinika, Brno
Neurology Department - Regional Hospital Pardubice, Pardubice
Department of Neurology and Center of Clinical Neuroscience, Charles University in Prague, 1st Faculty of Medicine and General University Hospital in Prague, Prague
Lead Sponsor
Ipsen
INDUSTRY